U.S., Nov. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07939295) titled 'Gene Therapy of Parkinson's Disease With KL002 in a Phase 1/2a Clinical Study' on Nov. 10.

Brief Summary: Evaluate the safety and tolerability of stereotactic injection of KL002 into the putamen of patients with advanced primary PD.

Study Start Date: Jan., 2027

Study Type: INTERVENTIONAL

Condition: Parkinson's Disease (PD) Advanced Primary PD

Intervention: GENETIC: Injecting KL002 into the bilateral putamen

KL002 is a recombinant adeno-associated virus (rAAV9) vector carrying TH, GCH1, and AADC genes

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Kanglin Biotechnology (Hangzhou) Co., Ltd.

Published by HT Digital Content S...